We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Fujifilm Enters Digital Pathology Space with Acquisition of Inspirata

By LabMedica International staff writers
Posted on 22 Dec 2022
Print article
Image: Dynamyx is FDA’s first and only clearance for digital pathology software with multiple scanners (Photo courtesy of Inspirata)
Image: Dynamyx is FDA’s first and only clearance for digital pathology software with multiple scanners (Photo courtesy of Inspirata)

Digital pathology is the digitization of pathology slides to conduct software visualization analysis of a specimen rather than using microscopic slides. With a specialty as image and data heavy as pathology, digitization is key. Pathologists, clinicians, patients, researchers and biopharma companies alike may see benefits such as improved and more efficient workflows, enhanced collaboration, remote and centralized interpretation, faster patient results, overall cost savings, ROI, and increased precision of diagnosis. Now, FUJIFILM Corporation (Tokyo, Japan) has entered into an asset purchase agreement to acquire the global digital pathology business of Inspirata, Inc. (Tampa, FL, USA). The addition of digital pathology will expand Fujifilm’s robust Synapse Enterprise Imaging offering to enable the integration of pathology images and data into a healthcare organization’s electronic health record system and help to streamline care delivery for oncology patients and provider teams.

Dynamyx is an open, vendor-agnostic, end-to-end digital pathology solution. Dynamyx’s software capabilities include using whole slide images from multiple scanning vendors to create an easier path for more pathology labs to digitize and realize the benefits of faster patient results, centralized imaging records, and enterprise access to images for all clinicians. It is installed in medical facilities that handle large volumes of pathological images across multiple lab locations, allowing the use of their preferred mix of laboratory and diagnostic technologies with confidence of full compatibility. Upon completion of the asset purchase agreement, Inspirata's Dynamyx digital pathology technology, employees and customers will become part of Fujifilm. Building off the success of its established partnership with Inspirata, this acquisition marks Fujifilm’s full-scale, global entry into the largely unpenetrated digital pathology market, where 85% of U.S., 86% of European, and 90% of Asian healthcare organizations are still running on analog.

Dynamyx will become part of Fujifilm’s Synapse Enterprise Imaging portfolio – an award-winning suite of healthcare IT solutions that unify imaging, data access and workflows across the health system. With the addition of digital pathology, Fujifilm will offer one of the most comprehensive enterprise imaging portfolios on the market consisting of a Best in KLAS winning VNA, Radiology PACS, and Cardiology PACS, as well as an enterprise information system, cloud services, and 3D advanced visualization. Future releases of Dynamyx will also create opportunities for Fujifilm to support pharmaceutical and contract research organizations with toxicity testing data management for drug development.

“Acquiring Inspirata’s digital pathology business allows Fujifilm to be an even stronger healthcare partner – bridging a technological gap between pathology, radiology and oncology to facilitate a more collaborative approach to care delivery across the enterprise,” said Teiichi Goto, president and CEO, representative director, FUJIFILM Corporation. “We’re thrilled to welcome Inspirata’s digital pathology experts to Fujifilm’s growing medical informatics business, along with their renowned global customer base, as together we work to drive the digitization and advancement of healthcare.”

“A USD 320 million global industry in 2021 projected to reach USD 640 million by 2025, the rising number of cancer cases and the demonstrated benefits of digital pathology are fueling significant demand and market growth in the hospital and pharmaceutical industries,” added Henry Izawa, president and CEO, FUJIFILM Healthcare Americas Corporation. “These evolving clinical needs fuel Fujifilm’s investment and innovation in the digital revolution, and we look forward to introducing Dynamyx and its host of unique features and benefits to our Synapse customers and prospects as we strive to enable more efficient medical diagnosis and high-quality care.”

“Since launching our European partnership with Inspirata three years ago, we’ve seen great success implementing our combined technologies in several healthcare organizations, notably in the UK,” said Masa Fukumoto, managing director, FUJIFILM Healthcare Europe and senior vice president FUJIFILM Medical Systems Europe. “We've received feedback from customers anticipating digitizing pathology will be the most transformative thing they do for their practice, and we look forward to continuing our global expansion.”

Related Links:
FUJIFILM Corporation
Inspirata, Inc.

HLX
Gold Supplier
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
New
Platinum Supplier
Ultra-Low PSA Control
Prostate-Specific Antigen Control
New
C-Reactive Protein Test
STANDARD F hs-CRP FIA

Print article

Channels

Clinical Chem.

view channel
Image: Electrochemical cells etched by laser on wooden tongue depressor measure glucose and nitrite in saliva (Photo courtesy of Analytical Chemistry)

Biosensor-Fabricated Wooden Tongue Depressor Measures Glucose and Nitrite in Saliva

Physicians often use tongue depressors to examine a patient's mouth and throat. However, it is hard to imagine that this simple wooden tool could actively assess a patient's health. This idea has led to... Read more

Molecular Diagnostics

view channel
Image: The Geo portable testing platform integrated with the Snap collection device (Photo courtesy of ReadyGo Diagnostics)

Ultra-Portable Rapid Test Platform Offers Complete Sample-to-Answer Solution for Remote and Off-Grid Testing

An ultra-portable isothermal molecular diagnostics system integrated with a patented device which combines sample collection and processing into a single, easy-to-use disposable is set to revolutionize... Read more

Hematology

view channel
Image: The Atellica HEMA 570 and 580 hematology analyzers remove workflow barriers (Photo courtesy of Siemens)

Next-Gen Hematology Analyzers Eliminate Workflow Roadblocks and Achieve Fast Throughput

Hematology testing is a critical aspect of patient care, utilized to establish a patient's health baseline, track treatment progress, or guide timely modifications to care. However, increasing constraints... Read more

Immunology

view channel
Image: Newly observed anti-FSP antibodies have also been found to predict immune-related adverse events (Photo courtesy of Calviri)

First Blood-Based Biomarkers Test to Predict Treatment Response in Cancer Patients

Every year worldwide, lung cancer afflicts over two million individuals and almost the same number of people succumb to the disease. This malignancy leads the charts in cancer-related mortalities, with... Read more

Microbiology

view channel
Image: The rapid MTB strip test for tuberculosis can identify TB patients within two hours (Photo courtesy of Chulalongkorn University)

Rapid MTB Strip Test Detects Tuberculosis in Less Than an Hour without Special Tools

Tuberculosis (TB), a highly infectious disease, continues to pose significant challenges to public health worldwide. TB is caused by a bacterium known as "Mycobacterium tuberculosis," spreading through... Read more

Pathology

view channel
Image: The UNIQO 160 (CE-IVDR) advances diagnostic analysis for autoimmune diseases (Photo courtesy of EUROIMMUN)

Novel Automated IIFT System Enables Cutting-Edge Diagnostic Analysis

A newly-launched automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics offers an all-in-one solution to enhance the efficiency of the complete IIFT process, comprising... Read more

Technology

view channel
Electronic biosensor uses DNA aptamers for detecting biomarkers in whole blood samples (Photo courtesy of Freepik)

Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents

The absence of robust, reliable, and user-friendly bioanalytical tools for early and timely diagnosis of cardiovascular diseases, particularly sudden cardiac arrest, leads to preventable deaths and imposes... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.